MetLife EVP reports stock grants and tax withholding

MetLife Inc. EVP & Chief Risk Officer Marlene Debel reported equity compensation transactions in company common stock.

Rhea-AI Filing Summary

MetLife Inc. EVP & Chief Risk Officer Marlene Debel reported equity compensation transactions in company common stock. On February 24, 2026, she acquired 15,132 shares at no cost as a restricted stock unit award under MetLife’s 2025 Stock and Incentive Compensation Plan and 14,870 shares from the performance-based payout of a 2023–2025 performance share award.

On the same date, 5,624 shares at $75.34 per share were withheld to cover her tax obligations related to the performance share payout. After these transactions, she directly owned 158,513 MetLife common shares. These movements reflect stock-based compensation and related tax withholding, not open‑market buying or selling.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider DEBEL MARLENE

Role EVP & Chief Risk Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,132	$0.00	$0.00
Grant/Award	Common Stock	14,870	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,624	$75.34	$424K

Holdings After Transaction: Common Stock — 158,513 shares (Direct)

Footnotes (3)

1. F1. Restricted stock unit award under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan.
2. F2. Shares acquired from the determination of the performance factor for and payout of 2023-2025 performance share award under the MetLife, Inc. 2015 Stock and Incentive Compensation Plan.
3. F3. Shares withheld to satisfy the reporting person's tax withholding obligation due on the performance share payout.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MetLife (MET) disclose for Marlene Debel?

MetLife’s EVP & Chief Risk Officer Marlene Debel reported equity compensation activity, including two stock awards and one tax-withholding share disposition. These transactions involved common shares granted at no cost and shares withheld to satisfy tax obligations from a performance share payout.

How many MetLife (MET) shares did Marlene Debel acquire in the latest Form 4?

Marlene Debel acquired 15,132 MetLife common shares from a restricted stock unit award and 14,870 shares from a 2023–2025 performance share payout. Both awards were recorded at a price of zero, reflecting stock-based compensation rather than open-market purchases.

Why were some MetLife (MET) shares disposed of in Marlene Debel’s Form 4?

The 5,624 MetLife shares shown as disposed were withheld to cover Marlene Debel’s tax obligations on the performance share payout. The shares were valued at $75.34 each and represent tax-withholding disposition, not an open-market sale of stock.

What is Marlene Debel’s MetLife (MET) share ownership after these transactions?

Following the reported equity awards and tax-withholding disposition, Marlene Debel directly owned 158,513 MetLife common shares. This total reflects the net result of the restricted stock unit grant, performance share payout, and the shares withheld to satisfy related tax liabilities.

What compensation plans are involved in Marlene Debel’s MetLife (MET) stock awards?

The transactions involve MetLife’s 2025 Stock and Incentive Compensation Plan and the 2015 Stock and Incentive Compensation Plan. One award is a restricted stock unit grant, while the other stems from a 2023–2025 performance share award whose payout determined additional common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:36 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEBEL MARLENE

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Risk Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		15,132	A	(1)	149,267	D
Common Stock	02/24/2026		A		14,870	A	(2)	164,137	D
Common Stock	02/24/2026		F(3)		5,624	D	$75.34	158,513	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan.

2. Shares acquired from the determination of the performance factor for and payout of 2023-2025 performance share award under the MetLife, Inc. 2015 Stock and Incentive Compensation Plan.

3. Shares withheld to satisfy the reporting person's tax withholding obligation due on the performance share payout.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.